Tech investors award AI startups that are reinventing work

Over the last six years, Dell Technologies Capital has plunked down more than $600 million to invest in startups focused on accelerating the “reinventing work” evolution. Microsoft’s M12 venture fund has shown similar enthusiasm.

CNBC’s Lori Ioannou parses out the meaning of the movement in an article posted July 16.

“According to Gartner, global business value derived from AI will reach a staggering $3.9 trillion by 2022,” she reports. “Yet legacy forms of data management for AI are counterproductive and not advanced enough.”

Among the sources Ioannou interviewed was Matthew Carroll, the CEO of Immuta, a startup whose data-governance platform attracted $20 million from Dell Technologies last year.

“Very soon in the future, I believe every employee will have automation tools and they will be data analysts doing their jobs every day,” Carroll said.

Meanwhile Nagraj Kashyap, global head of Microsoft’s M12, predicts AI will all but upend the workplace over the next 5 to 10 years.

“Innovation isn’t limited to … corporate boundaries,” Kashyap said. “It is an exciting time to see how AI is transforming the workplace. Already we see it becoming more distributed, more flexible and diverse.”

Ioannou didn’t drill down into healthcare, but as the No. 1 industry driving the U.S. economy according to Investopedia, it’s there between the lines.

Read the whole thing from CNBC:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.